MASI$178.39
$178.24
Chart
Performance
Key Stats
AI MASI Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyMasimo Corporation exhibits a mixed investment profile. Fundamentally, the company is navigating a challenging period with declining profitability and negative earnings, but its market position in patient monitoring offers some stability. Thematics are neutral, with no dominant growth drivers identified. Technicals indicate a stock that has experienced recent downward pressure but shows potential for short-term recovery. Investors should monitor earnings trends and competitive dynamics closely.
Thematic
Masimo operates in the healthcare technology sector, focusing on patient monitoring and automation solutions. While there are long-term trends supporting medical technology growth, such as an aging population and increasing demand for remote patient monitoring, the company is not currently a leader in disruptive thematic areas like AI or advanced biotechnology.
Fundamental
Masimo is experiencing significant financial headwinds. Recent quarters show negative net income and earnings per share, along with a declining net margin. While revenue has seen some growth historically, the latest data suggests a contraction. The balance sheet appears relatively stable, with manageable debt levels for the current market cap, but the negative earnings trend is a primary concern.
Technical
Masimo's stock price has experienced a notable decline, trading below key moving averages. However, recent performance shows some resilience, with positive short-term gains (5-day). Oscillators suggest the stock is neither overbought nor oversold, indicating potential for price movement in either direction. Moving averages generally signal a bearish trend, but the recent slight uptick warrants attention.
| Factor | Score |
|---|---|
| Healthcare Technology Advancements | 70 |
| AI in Healthcare | 30 |
| Remote Patient Monitoring | 65 |
| Medical Device Innovation | 50 |
| Regulatory Landscape | 60 |
| Factor | Score |
|---|---|
| Valuation | 35 |
| Profitability | 10 |
| Growth | 15 |
| Balance Sheet Health | 60 |
| Cash Flow | 65 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 45 |
| Volume Confirmation | 60 |
| Support & Resistance | 70 |
| Short-term Performance | 80 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Positive EPS Surprises
The company has a history of beating EPS estimates, with positive surprises in 10 out of the last 12 reported quarters. The latest quarter (2025 Q1) showed a surprise of 17.19% (reported $1.67 vs. estimate $1.43).
Revenue Growth Potential
Trailing twelve months (TTM) Price-to-Sales (P/S) ratio is 5.9, which, while not low, is accompanied by recent revenue growth. The company's revenue for 2024 was $2.09 billion.
Bearish Points (7)
Negative Net Income and EPS
The company reported a net income of -$304.9 million for 2024 and EPS of -$5.45 (TTM), indicating significant unprofitability in the latest fiscal year.
High Price-to-Sales Ratio
The Price-to-Sales (P/S) ratio for 2024 was 4.3, and for TTM it's 5.9. These are high relative to the negative net income, suggesting the stock is expensive based on current sales performance and not yet justified by profitability.
Calendar
November 2012
23
Ex-Dividend Date
December 2012
11
Next Dividend Date
August 2025
6
Next Earnings Date
H: $1.30
A: $1.22
L: $1.20
H: 372.10M
A: 368.65M
L: 367.30M
Profile
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, methemoglobin, hemoglobin, fractional arterial oxygen saturation, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow respiratory support therapy, neuromodulation technology, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.
Seasonals
Price Target
183.74 USD
The 39 analysts offering 1 year price forecasts for MASI have a max estimate of 200.00 and a min estimate of 158.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Global leader in medical technology, including patient monitoring, respiratory intervention, and critical care solutions, directly competing with Masimo in several areas.
Weight: 90
Strong presence in patient monitoring, diagnostic imaging, and connected care, a direct competitor to Masimo in hospital and home care settings.
Weight: 90
Major player in patient monitoring, diagnostic imaging, and healthcare IT, offering competing solutions for hospital and clinical use.
Weight: 88
Japanese medical electronics manufacturer, a significant global player in patient monitoring, EEG, and defibrillators, directly competing in medical device markets.